DuPont puts medical products businesses on the market
This article was originally published in Clinica
Executive Summary
US chemicals group DuPont wants to exit the medical devices sector, following in the footsteps of Eli Lilly. DuPont has put its four medical products businesses up for sale to part-finance $8,800 million share purchase from Seagram in April. DuPont had indicated before that it would sell about $2,000 million worth of assets to this end. The sale does not include DuPont's half share in DuPont Merck Pharmaceutical.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.